PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Prasugrel - Prevention of atherothrombotic events - Acute Coronary Syndrome

PAD Profile : Prasugrel - Prevention of atherothrombotic events - Acute Coronary Syndrome

Keywords :
ACS, dual antiplatelet therapy, triple antiplatelet therapy, DAPT
Brand Names Include :
Efient

Traffic Light Status

Status 1 of 1.

Status :
Blue
Important
Formulations :
  • Tablets
Important Information :
Restricted to cardiology consultants. Clopidogrel is the preferred option. Specialist initiation and at least one month supply before transfer to primary care
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
29 July 2020
Surrey Heartlands Medicines Safety Committee (MSC)

Co-prescribing of antiplatelets / anticoagulants may be requested by a specialist in a number of scenarios.

The Medicines safety Group have produced an aide memoire to list the information that must be available to the primary care clinican  to support the safe prescribing of dual / triple therapies in primary care.

See below for document: "Dual antiplatelet-anticoagulant therapy - Aide memoire for managing hospital requests"

01 February 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
A scheduled review of the expired information sheet has taken place and was approved at PCN. The place in therapy of antiplatelets in Acute Coronary Syndrome had previously been discussed by the PCN in January 2013 and the policy statement from those discussions still stands. See below for approved BLUE information sheet and policy statement (PCN 42-2013) from previous discussions.

Associated BNF Codes

02. Cardiovascular System
02.09.00. Antiplatelet drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More